159 related articles for article (PubMed ID: 30546143)
21. Proficiency testing of diagnosis in histopathology and immunohistochemistry of breast pathology in China: results from a pilot work of National Single Disease Quality Control Program for breast cancer.
Xue X; Guo L; Guo C; Li L; Yang L; Wang X; Rao W; Yuan P; Mu J; Li J; Wang B; Zhou Q; Yang W; Liu Y; Xue W; Jia R; Yang W; Ying J
BMC Cancer; 2024 Jan; 24(1):23. PubMed ID: 38166768
[TBL] [Abstract][Full Text] [Related]
22. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
Badowska-Kozakiewicz A; Sobol M; Patera J
Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
[TBL] [Abstract][Full Text] [Related]
23. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
24. Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
Bal O; Yalcintas Arslan U; Durnali A; Uyetrk U; Demirci A; Tastekin D; Ekinci A; Esbah O; Turker I; Uysal Sonmez O; Oksuzoglu B
J BUON; 2015; 20(1):28-34. PubMed ID: 25778292
[TBL] [Abstract][Full Text] [Related]
25. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
Bhargava R; Dabbs DJ
J Clin Oncol; 2012 Feb; 30(5):570-1. PubMed ID: 22231038
[No Abstract] [Full Text] [Related]
26. Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis.
Gertych A; Mohan S; Maclary S; Mohanty S; Wawrowsky K; Mirocha J; Balzer B; Knudsen BS
Diagn Pathol; 2014 Nov; 9():213. PubMed ID: 25421113
[TBL] [Abstract][Full Text] [Related]
27. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.
VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
Am J Surg Pathol; 2015 Jul; 39(7):939-47. PubMed ID: 25871620
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.
Rhodes A; Jasani B; Balaton AJ; Miller KD
J Clin Pathol; 2000 Apr; 53(4):292-301. PubMed ID: 10823126
[TBL] [Abstract][Full Text] [Related]
30. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
[TBL] [Abstract][Full Text] [Related]
31. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
32. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
East EG; Pang JC; Kidwell KM; Jorns JM
Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
[TBL] [Abstract][Full Text] [Related]
33. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.
Thunnissen E; Bovée JV; Bruinsma H; van den Brule AJ; Dinjens W; Heideman DA; Meulemans E; Nederlof P; van Noesel C; Prinsen CF; Scheidel K; van de Ven PM; de Weger R; Schuuring E; Ligtenberg M
J Clin Pathol; 2011 Oct; 64(10):884-92. PubMed ID: 21947301
[TBL] [Abstract][Full Text] [Related]
34. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
[TBL] [Abstract][Full Text] [Related]
35. HER2 status in elderly women with breast cancer.
Laird-Fick HS; Gardiner JC; Tokala H; Patel P; Wei S; Dimitrov NV
J Geriatr Oncol; 2013 Oct; 4(4):362-7. PubMed ID: 24472480
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
[TBL] [Abstract][Full Text] [Related]
37. [Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors].
Joubert C; Boissonneau S; Fina F; Figarella-Branger D; Ouafik L; Fuentes S; Dufour H; Gonçalves A; Charaffe-Jauffret E; Metellus P
Neurochirurgie; 2016 Jun; 62(3):151-6. PubMed ID: 27236733
[TBL] [Abstract][Full Text] [Related]
38. [Molecular characterization of breast cancer in clinical practice].
Zemmouri Y; De Croze D; Vincent Salomon A; Rouzier R; Bonneau C
Gynecol Obstet Fertil; 2016 May; 44(5):285-92. PubMed ID: 27150068
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
Chu JS; Lee WJ; Chen KM; Hsu HC
J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
[TBL] [Abstract][Full Text] [Related]
40. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
